On April 2, 2014, the Competition Bureau (Bureau) released draft
updated Intellectual Property Enforcement Guidelines (Revised
IPEGs) for a 60-day consultation period. The Revised IPEGs
principally reflect the amendments to the Competition Act
(Act) that have been made since the IPEGs were released in 2000
(2000 IPEGs). With one exception, the Revised IPEGs maintain the
same conceptual approach as the 2000 IPEGs regarding the interface
between competition policy and intellectual property (IP) rights.
However, the Revised IPEGs do not deal with some of the more recent
challenges – most notably the application of competition law
to pharmaceutical patent settlements, which have received extensive
attention from the U.S. Federal Trade Commission in recent years
and were the subject of a landmark decision of the U.S. Supreme
Court in 2013.1 In this regard, the Bureau appears not
to have closed the door on its willingness to elaborate on these
thorny issues and, in fact, has